ThyGenNEXT with Reflex to ThyraMIR
Order Name
ThyGenNEXT Rflx
Test Number: 6907017
Revision Date 10/01/2022
Test Number: 6907017
Revision Date 10/01/2022
Test Name | Methodology | LOINC Code |
---|---|---|
ThyGeNEXT
|
MicroRNA (miRNA) Profiling | n/a |
ThyraMIR
|
MicroRNA (miRNA) Profiling | n/a |
Nodule
|
Specimen Information | n/a |
Cytopathology
|
Patient Information | n/a |
Risk Assessment
|
Calculation | n/a |
ThyGen Interpretation
|
Interpretive information. | n/a |
SPECIMEN REQUIREMENTS | ||||
---|---|---|---|---|
Specimen | Specimen Volume (min) | Specimen Type | Specimen Container | Transport Environment |
Preferred | 1 Vial | Fine Needle Aspirate | RNARetain vial | Room Temperature |
Instructions | ThyGenNext testing is performed following an indeterminate FNA Cytology evaluation. Contact Labcorp Oklahoma, Inc. for FNA collection kit with special collection vial, instructions and requisition Specimen collection: Fine needle aspiration of thyroid nodule in RNARetain vial (small amount, 3rd or 4th pass) Specimen preparation: Send vial with cytology preparations at room temperature Stability: Ambient - 6 weeks Performing Lab Information and Requisition |
GENERAL INFORMATION | |
---|---|
Testing Schedule | Varies |
Expected TAT | 7-14 days after pathology interpretation |
Clinical Use | ThyGeNEXT® with Reflex to ThyraMIR® better discriminates benign from malignant nodules and provides risk assessment. TERT and BRAF mutations are included in ThyGeNEXT® . If mutations in ThyGeNEXT® are negative or not fully indicative of malignancy, the ThyraMIR® testing will be performed as reflex. |
Notes | INTERFACE ORDERING: ThyGenNEXT Rflx Order should be placed in addition to the electronic Cytology order. RESULT/REPORT CHANGE: ThyGenNEXT & ThyraMIR were previously reported as an addendum to the FNA Cytology report. They will now be reported from the General Laboratory section. |
CPT Code(s) | 0245U + 0018U if reflexed ThyraMIR Molecular testing is reflexed if mutations in ThyGeNEXT are negative or not fully indicative of malignancy. |
Lab Section | Reference Lab |